[Clinical Application of Alpha1 Adrenoceptor Antagonist Naftopidil to the Treatment of Chronic Non-Bacterial Prostatitis].

Xin Li,Ning-chen Li,Qiang Ding,Song-liang Cai,Hong-xu Huo,Shao-yan Chen,Xiao-jian Gu,Shi-ping Chen,Yan-qun Na
DOI: https://doi.org/10.3969/j.issn.1009-3591.2006.03.012
2006-01-01
Abstract:OBJECTIVE:To study the efficacy and safety of alpha1 adrenoceptor antagonist Naftopidil in the treatment of chronic non-bacterial prostatitis.METHODS:An opened, self-controlled, multicentral clinical trial was conducted. One hundred and six cases of patients who had been diagnosed as chronic non-bacterial prostatitis (NBP) were treated with Naftopidil (25 mg once a day) for 4 weeks. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the WBC in the examination of prostatic secretion (EPS) after the treatment.RESULTS:After 4 weeks therapy, 105 cases were evaluable. After treatment, NIH-CPSI total score were averagely decreased 12.0 points (P <0.001), symptom score 7.9 points (P <0.001) and QOL score 4.1 points (P <0.001). There was a statistically significant difference in WBC count ([(15.2 +/- 15.1)/HP vs (9.5 +/- 12.0)/HP, P < 0.01] and max flow rate(MFR) [(19.2 +/- 4.8) ml/s vs (22.7 +/- 4.9) ml/s, P < 0.01]. The total effective rate were 84.8% in the whole group. The clinical adverse rate was 3.81%, including 3 cases of mild dizziness and 1 case of mild inappetence.CONCLUSION:alpha1 adrenoceptor antagonist Naftopidil is effective and safe for the treatment of chronic non-bacterial prostatitis.
What problem does this paper attempt to address?